A Case-Based Clinical Approach to the Investigation, Management and Screening of Families with BRCA2 Related Prostate Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021:1–41. doi:10.3322/caac.21660.
   Web of Science ®Google Scholar
• Hjelmborg JB, Scheike T, Holst K, et al. The heritability of prostate cancer in the Nordic twin study of cancer. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2303–2310. doi:10.1158/1055-9965.EPI-13-0568
   PubMed Web of Science ®Google Scholar
• Attard G, Parker C, Eeles RA, et al. Prostate cancer. Lancet. 2016;387(10013):70–82. doi:10.1016/S0140-6736(14)61947-4
   PubMed Web of Science ®Google Scholar
• Farashi S, Kryza T, Clements J, Batra J. Post-GWAS in prostate cancer: from genetic association to biological contribution. Nat Rev Cancer. 2019;19(1):46–59. doi:10.1038/s41568-018-0087-3
   Web of Science ®Google Scholar
• Sipeky C, Talala KM, Tammela TLJ, Taari K, Auvinen A, Schleutker J. Prostate cancer risk prediction using a polygenic risk score. Sci Rep. 2020;10(1). doi:10.1038/s41598-020-74172-z
   Web of Science ®Google Scholar
• Zhen JT, Syed J, Nguyen KA, et al. Genetic testing for hereditary prostate cancer: current status and limitations. Cancer. 2018;124(15):3105–3117. doi:10.1002/cncr.31316
   PubMed Web of Science ®Google Scholar
• Robinson D, van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–1228. doi:10.1016/j.cell.2015.05.001
   PubMed Web of Science ®Google Scholar
• Abeshouse A, Ahn J, Akbani R, et al. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011–1025. doi:10.1016/j.cell.2015.10.025
   PubMed Web of Science ®Google Scholar
• Pilarski R. The role of BRCA testing in hereditary pancreatic and prostate cancer families. Am Soc Clin Oncol Educ Book. 2019;39(39):79–86. doi:10.1200/EDBK_238977
   Google Scholar
• Das S, Salami SS, Spratt DE, Kaffenberger SD, Jacobs MF, Morgan TM. Bringing prostate cancer germline genetics into clinical practice. J Urol. 2019;202(2):223–230. doi:10.1097/JU.0000000000000137
   PubMed Web of Science ®Google Scholar
• Nombela P, Lozano R, Aytes A, Mateo J, Olmos D, Castro E. BRCA2 and other DDR genes in prostate cancer. Cancers. 2019;11(3):352. doi:10.3390/cancers11030352
   PubMed Web of Science ®Google Scholar
• Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91(15):1310–1316. doi:10.1093/jnci/91.15.1310
   PubMedGoogle Scholar
• Kote-Jarai Z, Leongamornlert D, Saunders E, et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer. 2011;105(8):1230–1234. doi:10.1038/bjc.2011.383
   PubMed Web of Science ®Google Scholar
• Edwards SM, Kote-Jarai Z, Meitz J, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet. 2003;72(1):1–12. doi:10.1086/345310
   PubMed Web of Science ®Google Scholar
• Agalliu I, Karlins E, Kwon EM, et al. Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. Br J Cancer. 2007;97(6):826–831. doi:10.1038/sj.bjc.6603929
   Web of Science ®Google Scholar
• Schrader KA, Cheng DT, Joseph V, et al. Germline variants in targeted tumor sequencing using matched normal DNA. JAMA Oncol. 2016;2(1):104. doi:10.1001/jamaoncol.2015.5208
   PubMed Web of Science ®Google Scholar
• Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697–1708. doi:10.1056/nejmoa1506859
   PubMed Web of Science ®Google Scholar
• Castro E, Eeles R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl. 2012;14(3):409–414. doi:10.1038/aja.2011.150
   PubMed Web of Science ®Google Scholar
• Jenzer M, Keß P, Nientiedt C, et al. The BRCA2 mutation status shapes the immune phenotype of prostate cancer. Cancer Immunol Immunother. 2019;68(10):1621–1633. doi:10.1007/s00262-019-02393-x
   PubMed Web of Science ®Google Scholar
• Edwards SM, Dunsmuir WD, Gillett CE, et al. Immunohistochemical expression of BRCA2 protein and allelic loss at theBRCA2 locus in prostate cancer. Int J Cancer. 1998;78(1):1–7. doi:10.1002/(SICI)1097-0215(19980925)78:1<1::AID-IJC1>3.0.CO;2-U
   Web of Science ®Google Scholar
• Shore N, Oliver L, Shui I, et al. Systematic literature review of the epidemiology of advanced prostate cancer and Associated homologous recombination repair gene alterations. J Urol. 2021;205(4):977–986. doi:10.1097/JU.0000000000001570
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Gomella LG, Petrylak DP. When and how to use PARP inhibitors in prostate cancer: a systematic Review of the literature with an update on on-going Trials. Eur Urol Oncol. 2020;3(5):594–611. doi:10.1016/j.euo.2020.07.005
   PubMed Web of Science ®Google Scholar
• Ratta R, Guida A, Scotté F, et al. PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review. Prostate Cancer Prostatic Dis. 2020;23(4):549–560. doi:10.1038/s41391-020-0233-3
   Web of Science ®Google Scholar
• Swift SL, Lang SH, White H, Misso K, Kleijnen J, Quek RG. Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review. Future Oncol. 2019;15(28):3283–3303. doi:10.2217/fon-2019-0298
   PubMed Web of Science ®Google Scholar
• Lang S, Swift S, White H, Misso K, Kleijnen J, Quek R. A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer. Int J Oncol. 2019;55(3):597–616. doi:10.3892/ijo.2019.4842
   PubMed Web of Science ®Google Scholar
• Armstrong N, Quek RG, Ryder S, et al. DNA damage repair gene mutation testing and genetic counseling in men with/without prostate cancer: a systematic review. Future Oncol. 2021;17(7):853–864. doi:10.2217/fon-2020-0569
   Web of Science ®Google Scholar
• Oh M, Alkhushaym N, Fallatah S, et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: a meta-analysis. Prostate. 2019;79(8):880–895. doi:10.1002/pros.23795
   PubMed Web of Science ®Google Scholar
• Ramakrishnan Geethakumari P, Schiewer MJ, Knudsen KE, Kelly WK. PARP Inhibitors in Prostate Cancer. Curr Treat Options Oncol. 2017;18(6). doi:10.1007/s11864-017-0480-2
   Web of Science ®Google Scholar
• National Institute for Heath and Care Excellence. Prostate cancer: diagnosis and management NICE Guideline; 2019. Available from: www.nice.org.uk/guidance/ng131. Accessed May 5, 2021.
   Google Scholar
• Carter HB, Helfand B, Mamawala M, et al. Germline mutations in ATM and BRCA1/2 are associated with grade reclassification in men on active surveillance for prostate cancer. Eur Urol. 2019;75(5):743–749. doi:10.1016/j.eururo.2018.09.021
   PubMed Web of Science ®Google Scholar
• Gleicher S, Kauffman EC, Kotula L, Bratslavsky G, Vourganti S. Implications of high rates of metastatic prostate cancer in BRCA2 mutation carriers. Prostate. 2016;76(13):1135–1145. doi:10.1002/pros.23204
   Web of Science ®Google Scholar
• Wokołorczyk D, Kluźniak W, Huzarski T, et al. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland. Int J Cancer. 2020;147(10):2793–2800. doi:10.1002/ijc.33272
   Web of Science ®Google Scholar
• Na R, Zheng SL, Han M, et al. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol. 2017;71(5):740–747. doi:10.1016/j.eururo.2016.11.033
   PubMed Web of Science ®Google Scholar
• Castro E, Goh C, Leongamornlert D, et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol. 2015;68(2):186–193. doi:10.1016/j.eururo.2014.10.022
   PubMed Web of Science ®Google Scholar
• Akbari MR, Wallis CJD, Toi A, et al. The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer. Br J Cancer. 2014;111(6):1238–1240. doi:10.1038/bjc.2014.428
   Web of Science ®Google Scholar
• Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31(14):1748–1757. doi:10.1200/JCO.2012.43.1882
   PubMed Web of Science ®Google Scholar
• Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer. Eur Urol. 2016;69(6):992–995. doi:10.1016/j.eururo.2015.11.022
   PubMed Web of Science ®Google Scholar
• Zafeiriou Z, Bianchini D, Chandler R, et al. Genomic analysis of three metastatic prostate cancer patients with exceptional responses to carboplatin indicating different types of DNA repair deficiency. Eur Urol. 2019;75(1):184–192. doi:10.1016/j.eururo.2018.09.048
   PubMed Web of Science ®Google Scholar
• Pomerantz MM, Spisák S, Jia L, et al. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer. 2017;123(18):3532–3539. doi:10.1002/cncr.30808
   PubMed Web of Science ®Google Scholar
• Durkacz BW, Omidiji O, Gray DA, Shall S. (ADP-ribose)n participates in DNA excision repair. Nature. 1980;283(5747):593–596. doi:10.1038/283593a0
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–917. doi:10.1038/nature03443
   PubMed Web of Science ®Google Scholar
• Virtanen V, Paunu K, Ahlskog J, Varnai R, Sipeky C, Sundvall M. PARP inhibitors in prostate cancer—the preclinical rationale and current clinical development. Genes. 2019;10(8):565. doi:10.3390/genes10080565
   Web of Science ®Google Scholar
• Rimar KJ, Tran PT, Matulewicz RS, Hussain M, Meeks JJ. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. Cancer. 2017;123(11):1912–1924. doi:10.1002/cncr.30631
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–921. doi:10.1038/nature03445
   PubMed Web of Science ®Google Scholar
• Risdon EN, Chau CH, Price DK, Sartor O, Figg WD. PARP inhibitors and prostate cancer: to infinity and beyond BRCA. Oncologist. 2021;26(1). doi:10.1634/theoncologist.2020-0697
   Web of Science ®Google Scholar
• de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091–2102. doi:10.1056/NEJMoa1911440
   PubMed Web of Science ®Google Scholar
• Abida W, Campbell D, Patnaik A, et al. Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): updated analyses. Ann Oncol. 2019:30. doi:10.1093/annonc/mdz248.003.
   Google Scholar
• Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, Phase 2 trial. Lancet Oncol. 2020;21(1):162–174. doi:10.1016/S1470-2045(19)30684-9
   PubMed Web of Science ®Google Scholar
• Abida W, Patnaik A, Campbell D, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol. 2020;38(32):3763–3772. doi:10.1200/JCO.20.01035
   PubMed Web of Science ®Google Scholar
• Bouwman P, Jonkers J. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin Cancer Res. 2014;20(3):540–547. doi:10.1158/1078-0432.CCR-13-0225
   PubMed Web of Science ®Google Scholar
• Dhillon KK, Swisher EM, Taniguchi T. Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci. 2011;102(4):663–669. doi:10.1111/j.1349-7006.2010.01840.x
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152–1158. doi:10.1126/science.aam7344
   PubMed Web of Science ®Google Scholar
• Barber LJ, Sandhu S, Chen L, et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol. 2013;229(3):422–429. doi:10.1002/path.4140
   PubMed Web of Science ®Google Scholar
• Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008;451(7182):1111–1115. doi:10.1038/nature06548
   PubMed Web of Science ®Google Scholar
• Sakai W, Swisher EM, Jacquemont C, et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 2009;69(16):6381–6386. doi:10.1158/0008-5472.CAN-09-1178
   PubMed Web of Science ®Google Scholar
• Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008;451(7182):1116–1120. doi:10.1038/nature06633
   PubMed Web of Science ®Google Scholar
• Carneiro BA, Collier KA, Nagy RJ, et al. Acquired resistance to poly (ADP-ribose) polymerase inhibitor olaparib in brca2-associated prostate cancer resulting from biallelic BRCA2 reversion mutations restores both germline and somatic loss-of-function mutations. JCO Precis Oncol. 2018;(2):1–8. doi:10.1200/PO.17.00176
   Web of Science ®Google Scholar
• Ma Y, He L, Huang Q, et al. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report. BMC Med Genet. 2018;19(1). doi:10.1186/s12881-018-0703-9
   Web of Science ®Google Scholar
• Dasari S, Bernard Tchounwou P. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:740. doi:10.1016/j.ejphar.2014.07.025
   Web of Science ®Google Scholar
• Bouman-Wammes EW, van den Berg HP, de Munck L, et al. A randomised Phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: the RECARDO trial. Eur J Cancer. 2018;90:90. doi:10.1016/j.ejca.2017.11.021
   Web of Science ®Google Scholar
• Slootbeek PHJ, Duizer ML, Doelen MJ, et al. Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer. Int J Cancer. 2021;148(2):385–395. doi:10.1002/ijc.33306
   PubMed Web of Science ®Google Scholar
• Schmid S, Omlin A, Higano C, et al. Activity of platinum-based chemotherapy in patients with advanced prostate cancer with and without DNA repair gene aberrations. JAMA Netw Open. 2020;3(10):e2021692. doi:10.1001/jamanetworkopen.2020.21692
   PubMed Web of Science ®Google Scholar
• Mota JM, Barnett E, Nauseef JT, et al. Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations. JCO Precis Oncol. 2020;(4):355–366. doi:10.1200/PO.19.00346
   Web of Science ®Google Scholar
• Simmons AD, Nguyen M, Pintus E. Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report. BMC Cancer. 2020;20(1). doi:10.1186/s12885-020-6657-2
   Web of Science ®Google Scholar
• National Health Service. 2020/2021 national genomic test directory for cancer; 2020. Available from: https://www.england.nhs.uk/publication/national-genomic-test-directories/. Accessed February 6, 2021.
   Google Scholar
• Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119–1134. doi:10.1016/j.annonc.2020.06.011
   PubMed Web of Science ®Google Scholar
• Berner AM, Morrissey GJ, Murugaesu N. Clinical analysis of whole genome sequencing in cancer patients. Curr Genet Med Rep. 2019;7(2):136–143. doi:10.1007/s40142-019-00169-4
   Google Scholar
• Eeles R. Genetic predisposition to prostate cancer. Prostate Cancer Prostatic Dis. 1999;2(1):9–15. doi:10.1038/sj.pcan.4500279
   Web of Science ®Google Scholar
• Sokolova AO, Cheng HH. Genetic Testing in Prostate Cancer. Curr Oncol Rep. 2020;22(1). doi:10.1007/s11912-020-0863-6
   Web of Science ®Google Scholar
• Dean M, Campbell-Salome G, Rauscher EA. Engaging men with BRCA-related cancer risks: practical advice for BRCA risk management from male stakeholders. Am J Mens Health. 2020;14(3):155798832092493. doi:10.1177/1557988320924932
   Web of Science ®Google Scholar
• Donovan T, Flynn M. What makes a man a man? Cancer Nurs. 2007;30(6):464–470. doi:10.1097/01.NCC.0000300173.18584.37
   PubMed Web of Science ®Google Scholar
• Rauscher EA, Dean M, Campbell-Salome G, Barbour JB. “How do we rally around the one who was positive?” Familial uncertainty management in the context of men managing BRCA-related cancer risks. Soc Sci Med. 2019;242. doi:10.1016/j.socscimed.2019.112592
   Web of Science ®Google Scholar
• Skop M, Lorentz J, Jassi M, Vesprini D, Einstein G. “Guys Don’t Have Breasts”: the lived experience of men who have BRCA gene mutations and are at risk for male breast cancer. Am J Mens Health. 2018;12(4):961–972. doi:10.1177/1557988317753241
   Web of Science ®Google Scholar
• Dean M. “You have to be your own advocate”: patient self-advocacy as a coping mechanism for hereditary breast and ovarian cancer risk. Womens Health Advocacy. 2019;1–15.
   Google Scholar
• Pritchard C. New name for breast-cancer syndrome could help to save lives. Nature. 2019;571(7763):27–29. doi:10.1038/d41586-019-02015-7
   Web of Science ®Google Scholar
• Mahon SM. Cancer risks for men with BRCA1/2 mutations. Oncol Nurs Forum. 2014;41(1). doi:10.1188/14.ONF.99-101
   Web of Science ®Google Scholar
• Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. In: Adam MP, Ardinger HH, Pagon RA, et al. editors. GeneReviews^® [Internet]; University of Washington: Seattle. Initial Posting: September 4, 1998; Last Update: December 15, 2016. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1247/. Accessed May, 14, 2021.
   Google Scholar
• Hesse-Biber S, Within-Gender AC. Differences in medical decision making among male carriers of the BRCA genetic mutation for hereditary breast cancer. Am J Mens Health. 2017;11(5):1444–1459. doi:10.1177/1557988315610806
   Web of Science ®Google Scholar
• Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40–55 and long term risk of metastasis: case-control study. BMJ. 2013;346(apr15 5):f2023–f2023. doi:10.1136/bmj.f2023
   Web of Science ®Google Scholar
• Bancroft EK, Page EC, Castro E, et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT Study. Eur Urol. 2014;66(3):489–499. doi:10.1016/j.eururo.2014.01.003
   PubMed Web of Science ®Google Scholar
• Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125–132. doi:10.1093/jnci/djr500
   PubMedGoogle Scholar
• Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366(11):981–990. doi:10.1056/NEJMoa1113135
   PubMed Web of Science ®Google Scholar
• Roobol MJ, Steyerberg EW, Kranse R, et al. A risk-based strategy improves prostate-specific antigen–driven detection of prostate cancer. Eur Urol. 2010;57(1):79–85. doi:10.1016/j.eururo.2009.08.025
   Web of Science ®Google Scholar
• Ciatto S, Rubeca T, Confortini M, et al. Free to total PSA ratio is not a reliable predictor of prostate biopsy outcome. Tumori J. 2004;90(3):324–327. doi:10.1177/030089160409000311
   Web of Science ®Google Scholar
• Harvey P, Basuita A, Endersby D, Curtis B, Iacovidou A, Walker M. A systematic review of the diagnostic accuracy of prostate specific antigen. BMC Urol. 2009;9(1). doi:10.1186/1471-2490-9-14
   Google Scholar
• Page EC, Bancroft EK, Brook MN, et al. Interim results from the IMPACT Study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol. 2019;76(6):831–842. doi:10.1016/j.eururo.2019.08.019
   PubMed Web of Science ®Google Scholar
• Song WH, Kim SH, Joung JY, et al. Prostate cancer in a patient with a family history of BRCA mutation: a case report and literature Review. J Korean Med Sci. 2017;32(2):377. doi:10.3346/jkms.2017.32.2.377
   Web of Science ®Google Scholar
• Segal N, Ber Y, Benjaminov O, et al. Imaging-based prostate cancer screening among BRCA mutation carriers—results from the first round of screening. Ann Oncol. 2020;31(11):1545–1552. doi:10.1016/j.annonc.2020.06.025
   Web of Science ®Google Scholar
• Paluch-Shimon S, Cardoso F, Sessa C, et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol. 2016:27. doi:10.1093/annonc/mdw327.
   Web of Science ®Google Scholar